02.07.23
Civica, Inc. has selected Ypsomed AG as the manufacturer and supplier of insulin dosing injector pens for the company’s affordable insulins.
Civica announced previously that it intends to produce three insulin biosimilars—glargine, lispro and aspart. The products will be available both in vials and prefilled pens.
The company plans to sell the insulins at significantly lower prices than other insulins currently on the market.
“As a renowned injection device specialist with over 35 years’ experience, Ypsomed will help Civica make self-administered care more affordable for Americans living with diabetes,” said Ned McCoy, president and CEO of Civica. “Civica will deliver affordable, high-quality insulin, in the best pen platform, utilizing our new, state of the art manufacturing technology in Petersburg, Virginia.”
Civica expects to set a maximum recommended price to the consumer of no more than $30 per vial and no more than $55 for a box of five pen cartridges, a significant discount to prices charged to uninsured individuals today.
Subject to FDA approval, Civica anticipates that its insulins will be available for purchase beginning as soon as 2024.
Civica announced previously that it intends to produce three insulin biosimilars—glargine, lispro and aspart. The products will be available both in vials and prefilled pens.
The company plans to sell the insulins at significantly lower prices than other insulins currently on the market.
“As a renowned injection device specialist with over 35 years’ experience, Ypsomed will help Civica make self-administered care more affordable for Americans living with diabetes,” said Ned McCoy, president and CEO of Civica. “Civica will deliver affordable, high-quality insulin, in the best pen platform, utilizing our new, state of the art manufacturing technology in Petersburg, Virginia.”
Civica expects to set a maximum recommended price to the consumer of no more than $30 per vial and no more than $55 for a box of five pen cartridges, a significant discount to prices charged to uninsured individuals today.
Subject to FDA approval, Civica anticipates that its insulins will be available for purchase beginning as soon as 2024.
